SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending as the community eagerly anticipates the multi-billion dollar NASA Lunar Terrain Vehicle (LTV) contract award and upcoming earnings, following its recent $175 million strategic equity investment and the integration of its Lanteris acquisition. High short interest and broader enthusiasm for the "moon economy" are fueling significant volatility and debate around the stock's future in space infrastructure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as the market anticipates its pivotal Q4 earnings report, with sentiment sharply divided between expectations of a blowout performance driving new highs and concerns over a potential "sell the news" event. Discussions are also active around the future of AI demand, competition, and the upcoming Rubin AI system.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending following its strong earnings report, showcasing surging stablecoin demand and USDC circulation growth, igniting community debate around a potential short squeeze and its foundational role in digital finance, while others remain cautious given valuation concerns and ongoing regulatory hurdles.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to highly polarized reactions to Donald Trump's recent State of the Union address, where community discussion is intensely divided over his political rhetoric, economic claims, and controversy surrounding the Epstein files; this has investors and commentators sharply split between those celebrating the speech as a success that will drive the stock and those criticizing it as a "lie-a-thon" underscoring the company's speculative fundamentals.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending amid strong Q4 revenue growth from Tyvaso DPI sales and high anticipation for pivotal FDA decisions on Afrezza for pediatric diabetes and the Furoscix autoinjector. The community is actively debating whether these "catalyst-rich" developments signal a significant valuation increase or if historical performance and management concerns will continue to cap the stock's potential.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending following its earnings report, which highlighted its consistent "beat and raise" streak and AI-powered marketing platform's strong performance, sparking community discussion about its undervalued position despite ongoing software sector sell-offs.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent announcements of an innovation hub in India and a new "Sales Assist" agent, all ahead of its highly anticipated earnings report. Community discussion is focused on strong expectations for revenue growth and a path to profitability, with high short interest fueling speculation of a potential squeeze for its patented voice AI technology across automotive, QSR, and enterprise sectors.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is trending after projecting a significant revenue decline for its upcoming quarter, sparking a sharp sell-off and contrasting with its history of strong financial performance. The community is actively debating if the market reaction is an overcorrection and a buying opportunity, given the company's share buyback program, or if the stock faces further downside amidst an undefined bottom.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is trending after its 2026 sales guidance fell below consensus, prompting analyst downgrades and a stock decline. The community is actively debating if this creates a buying opportunity, weighing the near-term outlook against the company's strong US manufacturing position and potential tailwinds from AI data center energy demand.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending down sharply after its latest earnings report, despite beating EPS and revenue estimates, as cautious fiscal year 2027 revenue guidance amplifies broader market concerns about AI's disruptive impact on the software sector. The community is actively debating if the current sell-off is an overreaction to strong underlying fundamentals or a justified repricing given the evolving landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYCN More from 🦜 
 
Cyclerion (CYCN) at $1.37 per share and a $4.8M total market cap represents one of the most glaring sum-of-parts mispricings in all of small-cap biopharma: the market has become so fixated on the going-concern warning that it has stopped reading entirely, failing to compute that sitting inside this $4.8M shell is a $560 million contingent milestone stack from Akebia alone — 117 times the entire current market cap — plus tiered royalties on praliciguat ranging up to 20% of sales in a multi-billion dollar kidney disease market that the market is pricing at exactly zero; a 10% equity stake in Tisento Therapeutics carried at $5.35M on the books — already exceeding the entire CYCN market cap — but which is almost certainly worth $20-70M+ once Tisento announces its overdue Series B at a valuation reflecting its FDA Fast Track designation, fully enrolled global Phase 2b PRIZM study in MELAS, and top-tier VC backers including Invus, Sanofi Ventures, and Venrock,

StockTwits Web

Cyclerion Therapeutics Inc

 More from 🦜 
 
Cyclerion (CYCN) at $1.37 per share and a $4.8M total market cap represents one of the most glaring sum-of-parts mispricings in all of small-cap biopharma: the market has become so fixated on the going-concern warning that it has stopped reading entirely, failing to compute that sitting inside this $4.8M shell is a $560 million contingent milestone stack from Akebia alone — 117 times the entire current market cap — plus tiered royalties on praliciguat ranging up to 20% of sales in a multi-billion dollar kidney disease market that the market is pricing at exactly zero; a 10% equity stake in Tisento Therapeutics carried at $5.35M on the books — already exceeding the entire CYCN market cap — but which is almost certainly worth $20-70M+ once Tisento announces its overdue Series B at a valuation reflecting its FDA Fast Track designation, fully enrolled global Phase 2b PRIZM study in MELAS, and top-tier VC backers including Invus, Sanofi Ventures, and Venrock,

Marti Technologies Inc.

ODP Corporation (The)

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Avidity Biosciences Inc

Akebia Therapeutics Inc.

Monopar Therapeutics Inc

Cycurion Inc.

Twits Ghost

which the market is also pricing at zero; an olinciguat licensing process currently in active diligence with potential partners in a cardiovascular market where the sGC stimulator mechanism is already commercially validated with approved drugs, which the market is pricing at zero; an FDA-endorsed treatment-resistant depression program (CYC-126) with positive pre-IND written feedback received just two days ago, a five-member Clinical Advisory Board just assembled, and a Phase 2 study targeting initiation in H2 2026, which the market is pricing at zero; and an MIT-licensed CNS pipeline providing additional long-term optionality, which the market is — predictably — pricing at zero; the sum of even the most conservatively probability-weighted values across these five distinct asset categories produces a rational fair value of $83–200M+, implying a 17–60x repricing from today’s $1.37, and the catalysts to force that repricing are not speculative or years away

Clark K

they are actively converging right now, with boutique healthcare banker Vlad Ivanov at AmerX almost certainly working a confidential placement process armed with the FDA catalyst as his investor pitch anchor, a Tisento Series B that could be announced any week, and a going-concern clock that has already expired and makes a capital raise not optional but existential — meaning the market’s current pricing is not just wrong, it is wrong on five separate dimensions simultaneously, and the resolution of even one of those mispricings would likely produce a stock move that makes the others impossible to continue ignoring.​​​​​​​​​​​​​​​​

@StockTwitsGhost sorry but 5-15 percent chance they see any of the 500 Mill

$CYCN This 🐂🧸💩 talks out of both sides of his mouth , first downplaying it as a “5–15% chance” they ever received money from AKBA and saying millions already received are meaningless, then stretching timelines to 1–4 years while still dangling “$BIG.X$.” It’s constant contradiction with no consistent stance.

 sorry but 5-15 percent chance they see any of the 500 Mill

Quince Therapeutics Inc

SMX (Security Matters) PLC

Scisparc Ltd

VSee Health Inc.

Scienture Holdings Inc.

Check-Cap Ltd

Paul

@Bullbear1010101 They just received $1M, with additional performance milestones due later this year. Let’s not pretend otherwise. The dishonesty here is obvious. ✌🏽

 They just received $1M, with additional performance milestones due later this year. Let’s not pretend otherwise. The dishonesty here is obvious. ✌🏽

@StockTwitsGhost they need 50 million minimum. what is 1 million 
 
 
i hope they do but could be a year 
 
look at akba 1.1  was 4 last year  
 
doesnt look like progress . it might but who knows if or when  
 
maybe they make it to approval then still takes time  
 
so it could be 3-4 years a small chance of $BIG$ from them

 they need 50 million minimum. what is 1 million 
 
 
i hope they do but could be a year 
 
look at akba 1.1  was 4 last year  
 
doesnt look like progress . it might but who knows if or when  
 
maybe they make it to approval then still takes time  
 
so it could be 3-4 years a small chance of $BIG$ from them